Tenofovir disoproxil
- Generic Name
- Tenofovir disoproxil
- Brand Names
- Atripla, Cimduo, Complera, Delstrigo, Stribild, Symfi, Truvada, Viread, Tenofovir disoproxil Mylan
- Drug Type
- Small Molecule
- Chemical Formula
- C19H30N5O10P
- CAS Number
- 201341-05-1
- Unique Ingredient Identifier
- F4YU4LON7I
- Background
Tenofovir disoproxil fumarate (a prodrug of tenofovir), marketed by Gilead Sciences under the trade name Viread, belongs to a class of antiretroviral drugs known as nucleotide analogue reverse transcriptase inhibitors (nRTIs). This drug is prescribed in combination with other drugs for the management of HIV infection as well as for Hepatitis B therapy. Tenofovir disoproxil was initially approved in 2001 .
- Indication
Tenofovir disoproxil is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection in patients ≥2 years old and weighing ≥10 kg. It is also indicated for the treatment of chronic hepatitis B in patients ≥2 years old and weighing ≥10 kg.
Tenofovir disoproxil is also an ingredient in several combination products, all of which are indicated either alone or in combination with other antiretrovirals for the treatment of HIV-1 infection.
In addition, tenofovir disoproxil is available in combination with emtricitabine (under the brand name Truvada) for use as pre-exposure prophylaxis (PrEP) in at-risk adults and adolescents weighing ≥ 35kg to reduce the risk of sexually-acquired HIV-1 infection.
- Associated Conditions
- Chronic Hepatitis B Infection, Human Immunodeficiency Virus Type 1 (HIV-1) Infection
Optimization of Antiretroviral Therapy
- Conditions
- HIV Infections
- Interventions
- First Posted Date
- 2016-10-17
- Last Posted Date
- 2020-02-18
- Lead Sponsor
- Shanghai Public Health Clinical Center
- Target Recruit Count
- 184
- Registration Number
- NCT02935075
- Locations
- 🇨🇳
Yunnan AIDS care center, Kunming, Yunnan, China
🇨🇳The Second Hospital of Nanjing, Nanjing, Jiangsu, China
🇨🇳Shanghai Public Health Clinical Center, Shanghai, Shanghai, China
Evaluation of TNFα Blockers Monotherapy in Early Rheumatoid Arthritis in France
- Conditions
- Rheumatoid Arthritis
- First Posted Date
- 2016-10-07
- Last Posted Date
- 2016-10-07
- Lead Sponsor
- Centre Hospitalier Universitaire de Nīmes
- Target Recruit Count
- 813
- Registration Number
- NCT02927535
Evaluation of Tumour Necrosis Factor Alpha (TNFα) Blockers in Early Rheumatoid Arthritis in France
- Conditions
- Rheumatoid Arthritis
- First Posted Date
- 2016-10-07
- Last Posted Date
- 2016-10-07
- Lead Sponsor
- Centre Hospitalier Universitaire de Nīmes
- Target Recruit Count
- 813
- Registration Number
- NCT02927509
A Randomized, Open-label, Single-dosing, 2X2 Crossover Study to Compare the Safety and Pharmacokinetics of BR-TND Tablet(Tenofovir Disoproxil) With Viread Tablet(Tenofovir Disoproxil Fumarate) in Healthy Male Volunteers
- First Posted Date
- 2016-09-30
- Last Posted Date
- 2017-01-26
- Lead Sponsor
- Boryung Pharmaceutical Co., Ltd
- Target Recruit Count
- 50
- Registration Number
- NCT02920931
- Locations
- 🇰🇷
ChungNam university hospital, ChungNam, Korea, Republic of
A Study in Healthy Volunteers and Patients With Chronic Hepatitis B
- Conditions
- Chronic Hepatitis B
- Interventions
- Drug: Placebo for ABI-H0731Drug: Nucleos(t)ide
- First Posted Date
- 2016-09-20
- Last Posted Date
- 2019-04-04
- Lead Sponsor
- Assembly Biosciences
- Target Recruit Count
- 86
- Registration Number
- NCT02908191
PK and PD Study of Oral F/TAF for HIV Prevention
- Conditions
- HIV
- Interventions
- First Posted Date
- 2016-09-19
- Last Posted Date
- 2018-02-19
- Lead Sponsor
- CONRAD
- Target Recruit Count
- 73
- Registration Number
- NCT02904369
- Locations
- 🇺🇸
Eastern Virginia Medical School Clinical Research Center, Norfolk, Virginia, United States
🇺🇸Magee-Womens Research Institute and Foundation, Pittsburgh, Pennsylvania, United States
🇩🇴Profamilia, Santo Domingo, Dominican Republic
Clinical Trial to Assess the Safety and Pharmacokinetics of HUG116 Tablet and Viread® Tablet in Healthy Male Volunteers
- First Posted Date
- 2016-09-15
- Last Posted Date
- 2018-04-12
- Lead Sponsor
- Huons Co., Ltd.
- Target Recruit Count
- 50
- Registration Number
- NCT02902523
- Locations
- 🇰🇷
Huons, Seongnam-si, Gyeonggi-do, Korea, Republic of
Efficacy and Safety of Tenofovir Alafenamide (TAF) Versus Tenofovir Disoproxil Fumarate (TDF)-Containing Regimens in Participants With Chronic Hepatitis B Virus (HBV) Infection and Stage 2 or Greater Chronic Kidney Disease Who Have Received a Liver Transplant
- First Posted Date
- 2016-08-11
- Last Posted Date
- 2022-06-08
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 51
- Registration Number
- NCT02862548
- Locations
- 🇳🇿
Auckland City Hospital, Auckland, New Zealand
Andecaliximab as Add-On Therapy to a Tumor Necrosis Factor Inhibitor and Methotrexate Regimen in Adults With Moderately to Severely Active Rheumatoid Arthritis
- Conditions
- Rheumatoid Arthritis
- Interventions
- First Posted Date
- 2016-08-11
- Last Posted Date
- 2018-06-27
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 15
- Registration Number
- NCT02862574
- Locations
- 🇺🇸
Albuquerque Center for Rheumatology, Albuquerque, New Mexico, United States
🇺🇸Omega Research Consultants, LLC, DeBary, Florida, United States
🇺🇸Stanford University, Palo Alto, California, United States
Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate for Treatment of Hepatitis B e Antigen-Positive Hepatitis B (China)
- First Posted Date
- 2016-07-18
- Last Posted Date
- 2024-10-15
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 181
- Registration Number
- NCT02836249
- Locations
- 🇨🇳
Beijing Ditan Hospital, Beijing, China
🇨🇳PLA 302 Hospital, Beijing, China
🇨🇳Beijing Friendship Hospital, Capital Medical University, Beijing, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.